Literature DB >> 30117014

Are there any metastases to the chest in non-muscle-invasive bladder cancer patients on follow-up computed tomography?

Hiroshi Juri1, Mitsuhiro Koyama2, Haruhito Azuma3, Yoshifumi Narumi2.   

Abstract

PURPOSE: The purpose of the study was to retrospectively determine whether there are metastases to the chest in patients with primary non-muscle-invasive urothelial carcinoma in the bladder on the follow-up computed tomography (CT).
METHODS: We analyzed 328 patients with follow-up chest CT for urothelial carcinoma of the bladder diagnosed between January 2004 and September 2013. We divided patients into four groups: Ta (n = 74), T1 (n = 78), carcinoma in situ (CIS, n = 25), and ≥ T2 (n = 151). We used the chest CT to determine whether there were positive findings of metastasis. Univariate and multivariate analyses were achieved using categories of T stage, histological grade, multifocal lesions, and recurrence.
RESULTS: On univariate analysis, there were significant differences on T stage (p < 0.001) and histological grade (p = 0.001), and there was no significant difference on multifocal lesions (p = 0.11) and recurrence (p = 0.34). Positive findings of metastases were observed in 1.4% (1/74) of the Ta patients, 0% (0/78) of the T1 patients, 8.0% (2/25) of the patients with carcinoma in situ (CIS), and 27.2% (41/151) of the ≥ T2 patients (p < 0.001). On multivariate analysis, T staging was independent variable for positive findings of metastasis (Odds ratio; 2.84, 95% Confidence Interval; 1.65-4.89). In contrast, histological grade, multifocal lesions, and recurrence were not independent variables.
CONCLUSIONS: T stage would affect to metastasis to the chest. It might be appropriate to omit chest CT in patients with Ta or T1 without upstaging in the course of follow-up. We may suggest that the follow-up chest CT in patients with CIS.

Entities:  

Keywords:  Bladder cancer; CT; Chest; Follow-up; Metastasis

Mesh:

Year:  2018        PMID: 30117014     DOI: 10.1007/s11255-018-1952-4

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  18 in total

1.  Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  J Bellmunt; A Orsola; J J Leow; T Wiegel; M De Santis; A Horwich
Journal:  Ann Oncol       Date:  2014-08-05       Impact factor: 32.976

2.  Essential content of evidence-based clinical practice guidelines for bladder cancer: The Japanese Urological Association 2015 update.

Authors:  Yoshinobu Kubota; Noboru Nakaigawa
Journal:  Int J Urol       Date:  2016-07-03       Impact factor: 3.369

3.  Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor.

Authors:  Atul B Shinagare; Nikhil H Ramaiya; Jyothi P Jagannathan; Fiona M Fennessy; Mary-Ellen Taplin; Annick D Van den Abbeele
Journal:  AJR Am J Roentgenol       Date:  2011-01       Impact factor: 3.959

4.  Value of chest CT scans in routine ovarian carcinoma follow-up.

Authors:  T Sella; E Rosenbaum; D Z Edelmann; R Agid; A I Bloom; E Libson
Journal:  AJR Am J Roentgenol       Date:  2001-10       Impact factor: 3.959

Review 5.  Pathways of lymphatic spread in male urogenital pelvic malignancies.

Authors:  Blanca Paño; Carmen Sebastià; Laura Buñesch; Judit Mestres; Rafael Salvador; Napoleón G Macías; Carlos Nicolau
Journal:  Radiographics       Date:  2011 Jan-Feb       Impact factor: 5.333

6.  Lung metastasis of ta bladder cancer: a case report and literature review.

Authors:  Takeshi Sano; Shinshichi Hamada; Takao Haitani; Masakazu Nakashima; Yoichiro Kajita; Yasumasa Shichiri
Journal:  Korean J Urol       Date:  2013-04-16

7.  [Clinicopathological analysis on invasion and metastasis in superficial bladder cancer].

Authors:  Y Kakehi; Y Nishio; T Hashimura; H Takeuchi; O Yoshida
Journal:  Hinyokika Kiyo       Date:  1992-07

Review 8.  Superficial bladder cancer metastatic to the lungs: two case reports and review of the literature.

Authors:  David W Dougherty; Victoria K Gonsorcik; Lewis E Harpster; J C Trussell; Joseph J Drabick
Journal:  Urology       Date:  2008-04-18       Impact factor: 2.649

9.  Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.

Authors:  J Alfred Witjes; Thierry Lebret; Eva M Compérat; Nigel C Cowan; Maria De Santis; Harman Maxim Bruins; Virginia Hernández; Estefania Linares Espinós; James Dunn; Mathieu Rouanne; Yann Neuzillet; Erik Veskimäe; Antoine G van der Heijden; Georgios Gakis; Maria J Ribal
Journal:  Eur Urol       Date:  2016-06-30       Impact factor: 20.096

10.  Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Philippe E Spiess; Neeraj Agarwal; Rick Bangs; Stephen A Boorjian; Mark K Buyyounouski; Peter E Clark; Tracy M Downs; Jason A Efstathiou; Thomas W Flaig; Terence Friedlander; Richard E Greenberg; Khurshid A Guru; Noah Hahn; Harry W Herr; Christopher Hoimes; Brant A Inman; Masahito Jimbo; A Karim Kader; Subodh M Lele; Joshua J Meeks; Jeff Michalski; Jeffrey S Montgomery; Lance C Pagliaro; Sumanta K Pal; Anthony Patterson; Elizabeth R Plimack; Kamal S Pohar; Michael P Porter; Mark A Preston; Wade J Sexton; Arlene O Siefker-Radtke; Guru Sonpavde; Jonathan Tward; Geoffrey Wile; Mary A Dwyer; Lisa A Gurski
Journal:  J Natl Compr Canc Netw       Date:  2017-10       Impact factor: 11.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.